8-K: SI-BONE Reports Strong Preliminary Q4, FY2025 Revenue Growth

SI-BONE, Inc. announced preliminary unaudited revenue and cash for Q4 and full year 2025, showing robust growth and net cash generation.

Summary

• Preliminary unaudited worldwide revenue for Q4 2025 is between $56.2 million and $56.3 million, representing approximately 15% growth compared to the prior year period.
• Preliminary unaudited U.S. revenue for Q4 2025 is between $53.3 million and $53.4 million, representing approximately 14% growth compared to the prior year period.
• The company reported approximately 1,640 active physicians in the U.S. in Q4 2025, an increase of 250 physicians or about 18% growth.
• Cash and equivalents stood at approximately $147.7 million as of December 31, 2025, indicating net cash generation of about $2.0 million in the quarter.
• Preliminary unaudited worldwide revenue for fiscal year 2025 is between $200.8 million and $200.9 million, representing approximately 20% growth compared to the prior year.
• Preliminary unaudited U.S. revenue for fiscal year 2025 is between $190.9 million and $191.0 million, representing approximately 21% growth compared to the prior year.
• The company has achieved a +20% Revenue CAGR since its IPO in 2018 and recorded its third consecutive quarter of net cashflow breakeven.
• U.S. 4Q procedure volume grew by approximately 15% to 6,100 procedures compared to 5,300 in 4Q24.

Sentiment

Score: 8

Explanation: The filing reports strong preliminary revenue growth, significant physician adoption, and positive cash flow generation, indicating robust operational performance and market penetration. The company's innovative product pipeline and large addressable market further support a positive outlook, despite the preliminary nature of the financial figures.

Positives

• Strong preliminary worldwide revenue growth of approximately 15% for Q4 2025 and 20% for full year 2025.
• Robust preliminary U.S. revenue growth of approximately 14% for Q4 2025 and 21% for full year 2025.
• Significant increase in active U.S. physicians by 250, representing approximately 18% growth, indicating strong market penetration and engagement.
• Net cash generation of approximately $2.0 million in Q4 2025, leading to cash and equivalents of approximately $147.7 million.
• Achieved net cashflow breakeven for the third consecutive quarter, demonstrating improved operational efficiency.
• Maintained a +20% Revenue CAGR since its IPO in 2018, highlighting consistent long-term growth.
• Broad-based volume growth across all procedure types and 5 consecutive years of double-digit U.S. active physician growth every quarter.
• Possesses a market-leading platform for compromised bone procedural solutions with 3 Breakthrough Designated Devices, 72 issued patents, and 4 Randomized Controlled Trials.
• Identifies a large addressable market of over $3.5 billion in the U.S. with approximately 470,000 target annual procedures, with less than 10% currently penetrated.

Negatives

• The reported revenue and cash and equivalents are preliminary and unaudited, subject to completion of financial closing and audit procedures, and may be subject to adjustment.

Risks

• Preliminary fourth quarter and full year 2025 revenue and cash and cash equivalents are subject to continued review by the company and its auditors, and significant adjustments may be made before final results are determined.
• Ability to introduce and commercialize new products and indications.
• Ability to maintain favorable reimbursement for procedures using its products.
• Impact of any future economic weakness or deterioration in economic conditions, including as a result of tariffs and retaliation by U.S. trading partners, on the ability and desire of patients to undergo elective procedures using the company's products.
• Ability to manage risks to its supply chain.
• Future capital requirements driven by new surgical systems requiring instrument tray and implant inventory investment.
• The pace of the re-normalization of the healthcare operating environment, including the ability and desire of patients and physicians to undergo and perform procedures using the company's products.

Future Outlook

The company expects continued revenue and procedure growth, driven by commercial execution, physician engagement, innovation in its differentiated portfolio, and operational excellence. It anticipates expanding its sales force, deploying hybrid case coverage solutions, leveraging training and its comprehensive portfolio to drive physician growth and density, and accelerating penetration of its iFuse Bedrock Granite in the adult deformity and degeneration market, as well as building its pelvic trauma and interventional markets. The company also aims to increase revenue per territory and optimize the cost of surgical capacity.

Management Comments

• SI-BONE's expertise in additive manufacturing has resulted in a technology platform with market-leading applications in SI joint fusion, adult spinal deformity and pelvic trauma.
• A unique body of clinical evidence supports the use of SI-BONEs technologies, including four randomized controlled trials and over 200 peer reviewed publications.

Industry Context

SI-BONE operates in the competitive medical device sector, specifically focusing on procedural solutions for compromised bone, including SI joint fusion, adult spinal deformity, and pelvic trauma. Its preliminary results indicate strong growth, outpacing many traditional medical device segments, driven by innovation in 3D-printed implants and expanding physician adoption. The company's focus on large, underpenetrated markets and its robust clinical evidence base position it as a leader in its niche, particularly with its Breakthrough Device designations and strong patent portfolio.

Comparison to Industry Standards

• The company's +20% Revenue CAGR since its 2018 IPO demonstrates strong sustained growth, which is competitive within the high-growth segments of the medical device industry.
• SI-BONE's portfolio includes 3 Breakthrough Designated Devices (iFuse TORQ TNT, iFuse Bedrock Granite), which is a significant achievement compared to many competitors in the spinal and orthopedic device space, indicating leading-edge innovation.
• The company's extensive clinical evidence, including 4 Randomized Controlled Trials and over 200 peer-reviewed publications, sets a high standard for evidence-based medicine, often exceeding the clinical validation depth of many smaller or newer entrants in the orthopedic implant market.
• The identified total U.S. addressable market of over $3.5 billion for its products, with less than 10% penetrated, suggests a substantial growth runway compared to more mature or saturated segments of the medical device industry.

Stakeholder Impact

• Shareholders: Positive impact due to strong revenue growth, improved cash flow, and positive future outlook, potentially leading to increased share value.
• Employees: Potential for growth and expansion, particularly in sales and R&D, given the company's focus on commercial execution and innovation.
• Customers (Physicians): Increased product offerings and support, with a growing active physician base indicating satisfaction and continued adoption of SI-BONE's technologies.
• Patients: Benefit from continued innovation in procedural solutions for compromised bone, addressing unmet clinical needs in SI joint dysfunction, pelvic trauma, and adult spinal deformity.
• Suppliers: Potential for increased demand for components and materials as the company expands its product lines and market penetration.

Next Steps

• Completion of SI-BONE's financial closing procedures and audit procedures by its external auditors for Q4 and full year 2025.
• Provision of final fourth quarter and full year 2025 financial results during its Q4 2025 earnings call in late February 2026.
• Management team meetings with investors and analysts the week of January 12, 2026, to discuss company performance.
• Continued efforts to introduce and commercialize new products and indications.
• Ongoing focus on maintaining favorable reimbursement for procedures using its products.
• Expansion of sales force headcount and deployment of hybrid case coverage solutions.
• Leveraging training and comprehensive portfolio to drive physician growth and density.
• Expansion of residents and fellows academic training programs.
• Acceleration of penetration of iFuse Bedrock Granite in the adult deformity & degeneration market.
• Building the pelvic trauma market with iFuse TORQ TNT and the interventional market with iFuse TORQ and iFuse INTRA.
• Increasing revenue per territory and optimizing the cost of surgical capacity.

Key Dates

Recommendation

The preliminary results indicate exceptional growth in revenue and physician adoption, coupled with positive cash flow generation, which are strong indicators of operational success and market leadership. The company's robust pipeline of breakthrough devices, extensive patent protection, and a large, underpenetrated addressable market provide a compelling long-term growth story. While the results are preliminary, the consistent performance and strategic initiatives suggest significant upside potential for investors.

Keywords

SI-BONE, SIBN, Medical Devices, Spinal Surgery, Sacroiliac Joint Fusion, Pelvic Trauma, Adult Spinal Deformity, Financial Results, Revenue Growth, Cash Flow, Orthopedics, iFuse, 3D Printing, Healthcare